HYOF), the neuro-imaging specialist, played a key role in the US approval of a new blood test designed to help doctors identify signs of Alzheimer's disease in patients showing memory problems. The company provided imaging analysis for Fujirebio Diagnostics, a Japanese-owned diagnostics group, which in May secured regulatory clearance from the US Food and Drug Administration (FDA) for its new Lumipulse test. 